AzTrials
AzTrials

Total Joint ArthroplastyNCT05159739

Genetic Susceptibility to Periprosthetic Joint Infections

An observational study of Total Joint Arthroplasty and Periprosthetic Joint Infections, run by University of Utah at 1 site in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The investigators primary objective is to identify genetic factors that may increase the risk of patients developing a periprosthetic joint infections (PJI) following total joint arthroplasty (TJA). Read more about this study

Who is it for?
Ages 18 to 100 years
What is being tested?
Blood Draw or Saliva/Cheek Cell Sample:
How many people
150 participants
Where
1 siteUnited States
Study dates
7 Mar 2018to Mar 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • Adult, Older adult

Study population: Family members (affected and unaffected) with an increased incidence of TJI with PJI.

Who may be able to join

  • Families/pedigrees which demonstrate a high-risk for PJI
  • Unaffected family members, up to 3rd degree

Who cannot join

  • None

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site
  • University of Utah Orthopaedic Center

    Salt Lake City, Utah, 84108

Other trials in United States

About this study

Official title: Genetic Susceptibility to Periprosthetic Joint Infections of the Hip and Knee

The investigators primary objective is to identify genetic factors that may increase the risk of patients developing a periprosthetic joint infections (PJI) following total joint arthroplasty (TJA). The investigators hope that by identifying genetic predispositions we will be able to provide patient specific care pathways to prevent or minimize the risk for PJI.

Read the detailed description

Surgical site infections (SSI), and more specifically periprosthetic joint infections (PJI), have plagued the orthopaedic surgeon since the introduction of total joint arthroplasty (TJA) procedures of the hip or knee in the mid twentieth century. It is estimated that the economic burden of PJI in the United States will approach 1.62 billion USD by 2020. Though methods of infection control have improved, the rate of PJI appears to have plateaued in the last several decades. Early rates of PJI in the first two decades of THA have been reported between 1 - 9%. Since the 1980's studies have reported rates between 1% - 3%. It has been suggested that as orthopaedic surgeons, doctors should not be satisfied with deep infection rates greater than 1%. Therefore, more must be done in order to prevent, or diminish the frequency, of PJI and its devastating effects on this patient population.

In hopes of allowing for early targeted prevention in potentially high-risk patients, risk calculators have been developed to identify patients at greater risk for developing infection following TJA. However, some investigators suggest that these scoring systems may not be ready for primetime use. Thus, further research is needed to improve the ability to accurately identify individuals at high risk for infection. Unfortunately, the ability to perform large scale longitudinal cohort studies needed to create and test these risk calculators isn't feasible. Thus, other methods of early identification are needed.

Genetic susceptibility testing for identifying patients at risk for disease is becoming more popular and may be a means by which patients at high-risk for PJI can be identified. A recent dermatological study on genetic risk factors for infection suggest that host attributes may play a role in the ability of the individual to be infected. When evaluating the risk of subsequent different site infection in patients with multiple TJA's, investigators suggest that some patients may be at greater risk for infection due to possible subclinical immune deficiencies. In 2013, one investigator reported familial susceptibility to surgical site infections (SSI), including but not isolated to PJI, through a large population based study. Further, a recent publication from this investigating institution demonstrated familial clustering in patients who suffered a PJI, showing an increased risk of PJI following TJA in relatives of patients who have experienced PJI. These families demonstrated infection rates of 9 - 17%. After performing a systematic review on the genetic susceptibility to PJI, the investigators concluded that though evidence exists supporting a genetic role in PJI, no definitive conclusions can be made given the relatively small amount of data available in the existing literature. The investigators further emphasize the need for prospective studies to validate previous findings and the relationship between genetic factors and PJI.

Given the evidence in the literature, the investigators hypothesize that a large familial study will provide greater evidence of a genetic susceptibility. The results of this study could validate previous research with smaller sample sizes and allow for early identification of high-risk patients via genetic susceptibility testing.

Being tested
Blood Draw or Saliva/Cheek Cell Sample:
Keywords
total joint arthroplasty, periprosthetic joint infections, genetic susceptibility
Medical subject headings
Genetic Predisposition to Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Blood Draw or Saliva/Cheek Cell Sample:Genetic

    Also called Genetic sample

    Collected samples will immediately undergo genetic analysis to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.

Study groups in NCT05159739
Study groupRoleWhat they receive
Total Joint Arthroplasty (TJA)Recruitment of families with an increased incidence of TJI with PJI.
Receives: Genetic: Blood Draw or Saliva/Cheek Cell Sample:

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Genotyping

    Samples will undergo genetic testing to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.

    Measured: DNA extraction and analysis will be performed immediately after collection of blood draw or saliva/cheek cell sample by a certified core lab

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Dec 2021
  2. Study start7 Mar 2018
  3. Primary completionMar 2028 (estimated)
  4. Study completionMar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05159739
Sponsor's protocol ID
95940
Status last verified
Mar 2026
First submitted
2 Dec 2021
Last updated
19 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Total Joint Arthroplasty and Periprosthetic Joint Infections, run by University of Utah at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Genotyping (time frame: DNA extraction and analysis will be performed immediately after collection of blood draw or saliva/cheek cell sample by a certified core lab). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in